A Study of YL202 in Patients With Advanced Solid Tumors
A phase 2 trial of YL202 in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Overview
A Study of YL202 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07202364 by MediLink Therapeutics (Suzhou) Co., Ltd., with 100 participants planned, started 2025-08-04 and due to reach its primary completion in 2026-08-31. Interventions recorded: YL202. Conditions listed: Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
- TrialA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shares YL202, MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Shares YL202, MediLink Therapeutics.
- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
- TreatmentYL201
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TargetHER3
Shares YL202, Non-small-cell lung cancer.